| Literature DB >> 23543332 |
A M Aiken1, J B Haddow, N R A Symons, S Kaptanis, A C Katz-Summercorn, D Debnath, H Dent, S Tayeh, V Kung, S Clark, J Gahir, S Dindyal, S Farag, A Lazaridis, C P Bretherton, S Williams, A Currie, H West, J Davies, S Arora, A Kheraj, B M Stubbs, N Yassin, S Mallappa, G Garrett, S Hislop, A Bhangu, Y Abbey, I Al-Shoek, U Ahmad, G Sharp, A Memarzadeh, A Patel, F Ali, H Kaderbhai, C H Knowles.
Abstract
PURPOSE: Evidence regarding whether or not antibiotic prophylaxis is beneficial in preventing post-operative surgical site infection in adult inguinal hernia repair is conflicting. A recent Cochrane review based on 17 randomised trials did not reach a conclusion on this subject. This study aimed to describe the current practice and determine whether clinical equipoise is prevalent.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23543332 PMCID: PMC3788180 DOI: 10.1007/s10029-013-1061-3
Source DB: PubMed Journal: Hernia ISSN: 1248-9204 Impact factor: 4.739
Fig. 1SHAPE study flowchart
Hospital guidelines for antibiotic prophylaxis in inguinal hernia repair with mesh
| Recommended regimen | Number of sites |
|---|---|
| Co-amoxiclav 1.2 g IV | 7 |
| Co-amoxiclav 1.2 g IV and gentamicin 160 mg IV | 1 |
| Cefuroxime 1.5 g IV | 6 |
| Cefuroxime 1.5 g and metronidazole 500 mg IV | 4 |
| Cefuroxime 750 mg IV and metronidazole 500 mg IV | 1 |
| Gentamicin 240 mg IV and metronidazole 500 mg IV | 1 |
| Gentamicin 3 mg/kg and metronidazole 1 g IV | 1 |
| Gentamicin 160 mg IV and metronidazole 500 mg IV and amoxicillin 500 mg IV | 1 |
| No antibiotics to be used | 5 |
| Guidelines in place with no clear recommendation | 1 |
| No guidelines currently in place | 6 |
| Total | 34 |
Antibiotic prophylaxis agents for use in open and laparoscopic inguinal hernia repair
| Antibiotic prophylaxis regimen | Open (%) | Laparoscopic (%) |
|---|---|---|
| No antibiotics | 28 (13) | 28 (20) |
| Co-amoxiclav 1.2 g IV | 118 (53) | 74 (52) |
| Co-amoxiclav 625 mg IVa | 1 (0) | 2 (1) |
| Co-amoxiclav 375 mg IVa | 1 (0) | 0 (0) |
| Co-amoxiclav 1.2 g and metronidazole 500 mg IV | 2 (1) | 2 (1) |
| Co-amoxiclav 1.2 g and gentamicin 160 mg IV | 5 (2) | 3 (2) |
| Co-amoxiclav 1.2 g IV and gentamicin 80 mg applied topically to mesh | 2 (1) | 1 (1) |
| Cefuroxime 1.5 g IV | 25 (11) | 7.5 (5) |
| Cefuroxime 750 mg IV | 9 (4) | 5 (3) |
| Cefuroxime 1.5 g and metronidazole 500 mg IV | 6 (3) | 1 (1) |
| Cefuroxime 750 mg and metronidazole 500 mg IV | 2 (1) | 2 (1) |
| Cefuroxime 750 mg IV and 80 mg gentamicin applied topically to mesh | 1 (0) | 0 (0) |
| Flucloxacillin 1 g IV | 1 (0) | 1 (1) |
| Flucloxacillin 500 mg and amoxicillin 500 mg IV | 1 (0) | 1 (1) |
| Flucloxacillin 500 mg and gentamicin 120 mg IV | 2 (1) | 0 (0) |
| Flucloxacillin 500 mg and gentamicin 80 mg IV | 1 (0) | 1 (1) |
| Flucloxacillin 500 mg IV | 0.5 (0) | 0.5 (0) |
| Gentamicin 160 mg and amoxicillin 500 mg and metronidazole 500 mg IV | 1 (0) | 1 (1) |
| Gentamicin 4 mg/kg and metronidazole 500 mg IV | 2 (1) | 2 (1) |
| Gentamicin 3 mg/kg and metronidazole 1 g IV | 3 (1) | 3 (2) |
| Gentamicin 120 mg and metronidazole 500 mg IV | 1 (0) | 1 (1) |
| Gentamicin 240 mg and metronidazole 500 mg IV | 3 (1) | 1 (1) |
| Tazocin 4.5 g IV | 0.5 (0) | 0 (0) |
| Ertapenem 1 g IV | 4.5 (2) | 3.5 (2) |
| Clindamycin 600 mg IV | 0.5 (0) | 0.5 (0) |
| Use prophylaxis but choice of drug unclear | 2 (1) | 2 (1) |
| Total | 223 (100) | 143 (100) |
Wherever a surgeon did not express a clear preference (e.g. “I use either A or B”), this was evaluated as an even split of preference, such that the sum of an individual’s responses came to one (e.g. A = 0.5, B = 0.5)
aPreparation does not exist in the British National Formulary (www.bnf.org)—responses are given as reported
Fig. 2Surgeons’ beliefs on the use of prophylactic antibiotics for elective inguinal hernia repair (n = 229)